SMARCA4 and ovarian cancer: While the above-described experiments show that SMARCA4 inhibition results in increased NK infiltration in a murine model of ovarian cancer, we observed increased ascites formation and no reduction in tumor size upon intraperitoneal injection with the SMARCA4 PROTAC AU-15330.